AbbVie
ABBV
2,658 hedge funds and large institutions have $127B invested in AbbVie in 2021 Q3 according to their latest regulatory filings, with 120 funds opening new positions, 1,348 increasing their positions, 870 reducing their positions, and 97 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 1,348 | Existing positions reduced: 870
24% more first-time investments, than exits
New positions opened: 120 | Existing positions closed: 97
0.35% less ownership
Funds ownership: 67.04% → 66.69% (-0.35%)
1% less funds holding
Funds holding: 2,677 → 2,658 (-19)
1% less call options, than puts
Call options by funds: $2.27B | Put options by funds: $2.29B
5% less capital inflows, than outflows
Capital inflows: $6.6B | Capital outflows: $6.97B
4% less funds holding in top 10
Funds holding in top 10: 139 → 134 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.02B |
| 2 |
BlackRock
New York
|
+$485M |
| 3 |
Goldman Sachs
New York
|
+$346M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$325M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$278M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.58B |
| 2 |
Berkshire Hathaway
Omaha,
Nebraska
|
-$700M |
| 3 |
Orbis Allan Gray
Hamilton,
Bermuda
|
-$414M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$319M |
| 5 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$268M |
ABBV Hedge Fund Activity: Q3 2021 in Review
2,658 of the 5,731 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q3 2021, worth a combined $127B — down 4.6% from $133B a quarter earlier.
Buyers outnumbered sellers: 120 funds opened new ABBV positions and 97 closed out — a net gain of 23 holders — while 1,348 added to existing stakes and 870 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $1.02B. The largest seller was Fidelity Investments, cutting an estimated $1.58B.
- 2,658 institutional investors held AbbVie (ABBV) as of Q3 2021, down from 2,677 in Q2 2021.
- Funds reported $127B of AbbVie stock for Q3 2021, down 4.6% quarter-over-quarter.
- 120 funds opened new AbbVie positions in Q3 2021 and 97 closed out, a net change of +23 holders.
- The largest AbbVie buyer in Q3 2021 was JP Morgan Chase, an estimated $1.02B added.
- The largest AbbVie seller in Q3 2021 was Fidelity Investments, an estimated $1.58B sold.
Based on aggregated 13F filings for Q3 2021.